Change in BLS Management: Ronan Donohue assumes the role of President for the Global Business Unit Biopharma and Life Sciences

Donohue brings a wealth of international business leadership and experience, having worked extensively in the US, Europe, and the Middle East over the past twenty-five years, providing design and construction solutions to a diverse range of life sciences and advanced technology clients. "With Ronan Donohue at the helm of the Global Business Unit Biopharma and Life Sciences, an experienced industry expert takes the lead. Under his guidance, the business unit is expected to accelerate its growth and make a significant contribution to our 'Pathway to Ten' goals," says Büchele. 

"I look forward to leading and shaping the future of Exyte’s Biopharma and Life Sciences business segment together with the global BLS team. The markets in which we operate are poised for continued strong growth in the coming years. The GBU BLS, with its technology expertise and full-service delivery offering, is well-positioned to capitalize on this growth," Donohue stated. 

Donohue was appointed Executive Vice President of BLS in May 2021. He holds an engineering degree from Technological University Dublin and is a Fellow of Engineers Ireland. Additionally, he earned an MBA from University College Dublin. 

Miller joined Exyte in 2019. He assumed the dual roles of President of BLS and Senior Vice President of Exyte's US operations, leading both organizations through the global pandemic. Miller has played a pivotal role in building the global BLS organization and significantly expanded the business. "I would like to extend my gratitude to Chris Miller for his leadership and contributions. Over the past few years, the Global Business Unit BLS has successfully executed significant market-leading projects and secured new, strategically relevant clients. With great dedication, Chris Miller has driven technical innovations such as ExyCell©, ExyVision and other digitalization-focused innovations within the business unit," emphasized Büchele. 

In 2022 Exyte’s Biopharma and Life Sciences segment reached sales of 610 million euro, an increase of 71 percent compared to 2021, while the order intake rose by 18 percent to 581 million euro. The business segment offers complete solutions for clients in the biotechnology, pharmaceutical, medical technology, food and nutrition, and consumer care sectors. The range of services includes the overall planning, engineering, construction, commissioning, and qualification of production facilities that comply with industry-specific and legal requirements.